Semax
Select Size
$29.99
A synthetic heptapeptide analog of ACTH(4-10), modified with a C-terminal Pro-Gly-Pro fragment to improve stability and biological activity. Semax has been investigated in neurobiology-focused research for its effects on neurotrophic signaling, stress-response pathways, and neural recovery models.
Certificate of Analysis
Third-party verified · HPLC & Mass Spectrometry
Purity
99.456%
Search Code
Coff2512150079
Test Date
Dec 15, 2025
Laboratory
Freedom Diagnostics
Compound Details
Mechanism of Action
Semax is a melanocortin-derived peptide that appears to modulate central neurotrophic and neurotransmitter systems, including BDNF-related signaling, while also influencing stress-responsive and inflammatory gene expression pathways in neural tissue models.
Molecular Profile
- Molecular Weight
- 813.93 Da
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro (7 amino acids)
- Purity Spec
- >=98% by HPLC
Storage
Store lyophilized at -20°C. Reconstituted: 2-8°C, use within 21 days. Protect from light and avoid repeated freeze-thaw cycles.
Research Applications
Published Research
Peer-reviewed studies from PubMed.
- Semax, an analogue of adrenocorticotropin (4-10), is a ...2006Foundational
Foundational Semax report describing biologic activity of the ACTH(4-10)-derived analog and positioning it as a neuroactive peptide with non-hormonal signaling relevance.
- Characterized Semax as an ACTH-fragment-derived neuroactive peptide
- Supported non-classical endocrine profile relative to full ACTH
- Provided early translational framing for CNS-focused investigations
Preclinical study indicating Semax modulates temporal expression of BDNF and NGF genes in rat brain regions relevant to learning, memory, and stress response.
- Reported changes in BDNF and NGF gene-expression dynamics after Semax
- Supports neurotrophic-pathway hypothesis for Semax activity
- Provided molecular context for later neuroprotection studies
- The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system2004Neuroprotection
Preclinical Parkinsonian-lesion model study reporting Semax-associated neuroprotective effects in dopaminergic system injury context.
- Demonstrated protective effects in MPTP-related dopaminergic injury model
- Extended Semax relevance beyond trophic markers to lesion outcomes
- Supported investigation in neurodegeneration-oriented research settings
